Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Cancer Discov. 2018 Aug 28;8(10):1258–1269. doi: 10.1158/2159-8290.CD-18-0743

Figure 1. Schema of Clinical Trial.

Figure 1.

Patients underwent treatment at Lesion A with radiation (XRT) with 2 Gy per day on Days 1 and 2. Starting after XRT on Day 2, patients received five weekly intratumoral injections at the treated site (Lesion A) with the TLR9 agonist, SD-101. Treatment response was evaluated 90-day and 180-days post-treatment and every 6 months thereafter. FNA biopsies were collected pretreatment (Day 1) and post-initial treatment (Day 9) at Lesion A and, if available, at a single distal site, Lesion B.